Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROCREAM vs METRO I.V.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Treatment of intra-abdominal infections (e.g., peritonitis, abscess),Treatment of pelvic inflammatory disease,Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (intestinal and extraintestinal),Treatment of anaerobic infections (e.g., bone and joint, central nervous system, respiratory tract, skin and soft tissue),Perioperative prophylaxis (colorectal surgery),Off-label: Helicobacter pylori eradication (with other agents), rosacea (topical), Crohn's disease (perianal fistulas)
Topical, apply a thin film to affected area once or twice daily.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Metronidazole is extensively metabolized in the liver via oxidation and glucuronidation. The major metabolic pathways involve hydroxylation and side-chain oxidation, mediated by CYP450 enzymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4). The primary metabolites are 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-acetic acid, which have minimal antimicrobial activity.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Metronidazole: <20% bound to plasma proteins.
<20%, primarily to albumin.
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
0.6-0.7 L/kg; indicates extensive distribution into tissues including CSF and abscess cavities.
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
Oral: 80-90%; IV: 100%.
No adjustment required for topical application.
Cr Cl > 50 m L/min: no adjustment; Cr Cl 10-50 m L/min: increase dosing interval to every 12 hours; Cr Cl < 10 m L/min: increase interval to every 24 hours.
No adjustment required for topical application.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
Safety and efficacy not established in pediatric patients under 18 years.
Loading dose: 15-30 mg/kg IV; maintenance: 7.5 mg/kg IV every 6 hours. For neonates < 7 days: 15 mg/kg IV every 24 hours; 7-28 days: 15 mg/kg IV every 12 hours.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
Use with caution; adjust dose based on renal function (Cr Cl) and monitor for neurotoxicity. Start at lower end of dosing range.
None
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. It should be used only for approved indications and for the shortest duration necessary.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Carcinogenicity: Avoid unnecessary use,Peripheral neuropathy: Risk with high doses or prolonged treatment; discontinue if signs occur,Central nervous system effects: Encephalopathy, convulsions, aseptic meningitis; discontinue if symptoms develop,Hepatotoxicity: Risk of severe hepatic injury, including acute liver failure; monitor liver function,Blood dyscrasias: Leukopenia, neutropenia; caution in patients with history of blood disorders,Interaction with alcohol: Disulfiram-like reaction (nausea, vomiting, flushing); avoid alcohol during therapy and for at least 3 days after,Cochrane interaction: Increased INR with warfarin; monitor INR,Renal impairment: Accumulation of metabolites; dosage adjustment may be needed,Prolonged therapy: Monitor for superinfection and neurological symptoms
Hypersensitivity to metronidazole or any component of the formulation.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (unless alternative treatments not available),Breastfeeding (withhold nursing for 12-24 hours after dose),Concurrent use of disulfiram (psychotic reactions may occur),Severe hepatic impairment (metronidazole is hepatically cleared)
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
No significant food interactions. However, alcohol is strictly contraindicated. Use alcohol-free formulations of medications and avoid alcoholic beverages.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Excreted in breast milk in low concentrations; M/P ratio approximately 1.0. Considered compatible with breastfeeding; monitor infant for diarrhea or candidiasis.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
No specific dose adjustment required in pregnancy; pharmacokinetics not significantly altered. Use standard dosing based on infection severity and renal function.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
METRO I. V. (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It has excellent bioavailability following intravenous administration. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). May cause metallic taste, which is benign. Use with caution in patients with CNS disorders due to risk of seizures.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
Do not drink any alcohol or take products containing alcohol (e.g., mouthwash, cough syrup) while using this medication and for 48 hours after stopping, as it can cause severe nausea, vomiting, headache, and abdominal cramps.,May cause a metallic or bitter taste in the mouth; this is harmless and temporary.,Report any numbness, tingling, or weakness in your arms or legs to your healthcare provider immediately, as this could be a sign of nerve damage.,Take the full course of therapy exactly as prescribed, even if you feel better.,If you have severe liver disease, your dose may need to be adjusted.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROCREAM vs METRO I.V., answered by our medical review team.
METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. METRO I.V. is a Antibiotic (Nitroimidazole) that works by Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROCREAM and METRO I.V. depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. The standard adult dose of METRO I.V. is: 15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROCREAM and METRO I.V. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. METRO I.V. is classified as Category C. Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.